We also found evidence that a three-gene signature consisting of BOLL, DCC, SFRP2 can be used for therapy stratification in CRC patients with liver metastasis to monitor the response to neoadjuvant chemotherapy. This evidence concerns the gene DCC and colorectal carcinoma.